Stent coating
First Claim
1. An implantable stent prosthesis for delivering a biologically active material to a patient comprising:
- (a) a stent body having a surface adapted for exposure to body tissue of the patient;
(b) a coating disposed over at least a portion of the surface of the stent body;
wherein the coating comprises;
(i) a biologically active material selected from the group consisting of anti-thrombogenic agents, anti-angiogenesis agents, anti-proliferative agents, growth factors, radiochemicals, and lovastatin; and
(ii) a mixture of a first co-polymer and a second co-polymer, wherein said first co-polymer releases the biologically active material at a first rate and said second co-polymer releases the biologically active material at a second rate, wherein said second rate is slower than said first rate.
0 Assignments
0 Petitions
Accused Products
Abstract
A stent having a polymeric coating for controllably releasing an included active agent. The polymeric coating includes a blend of a first polymeric material, which if alone, would release the agent at a first, higher rate, and a second polymeric material, which if alone would release the agent at a second, lower rate over a longer time period. One stent coating utilizes a faster releasing hydrophilic polymeric material and a slower releasing hydrophobic material. One stent coating includes a blend of a faster releasing PLA-PEO copolymer and a slower releasing PLA-PCL copolymer. One active agent is Taxol. One use of the Taxol delivering stent is to inhibit restenosis following angioplasty.
-
Citations
34 Claims
-
1. An implantable stent prosthesis for delivering a biologically active material to a patient comprising:
-
(a) a stent body having a surface adapted for exposure to body tissue of the patient;
(b) a coating disposed over at least a portion of the surface of the stent body;
wherein the coating comprises;
(i) a biologically active material selected from the group consisting of anti-thrombogenic agents, anti-angiogenesis agents, anti-proliferative agents, growth factors, radiochemicals, and lovastatin; and
(ii) a mixture of a first co-polymer and a second co-polymer, wherein said first co-polymer releases the biologically active material at a first rate and said second co-polymer releases the biologically active material at a second rate, wherein said second rate is slower than said first rate.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. A method of making an implantable stent prosthesis for delivering a biologically active material to a patient, wherein said method comprises:
-
(a) providing a stent body having a surface adapted for exposure to body tissue of the patient;
(b) applying a coating over at least a portion of said surface;
wherein said coating comprises;
(i) a biologically active material selected from the group consisting of anti-thrombogenic agents, anti-angiogenesis agents, anti-proliferative agents, growth factors, radiochemicals, and lovastatin; and
(ii) a mixture of a first co-polymer and a second co-polymer, wherein said first co-polymer releases said biologically active material at a first rate and said second co-polymer releases said biologically active material at a second rate, and wherein said second rate is slower than said first rate.- View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)
-
-
26. An implantable stent prosthesis for delivering a restinosis inhibiting agent to a patient comprising:
-
(a) a stent body having a surface adapted for exposure to body tissue of the patient;
(b) a coating disposed over at least a portion of the surface of the stent body, wherein the coating comprises;
(i) the restinosis inhibiting agent selected from the group consisting of paclitaxel, paclitaxel analogues, paclitaxel derivatives, and combinations thereof; and
(ii) a mixture of about 50% by weight of a copolymer of polylactic acid/polyethylene oxide and about 50% by weight of a copolymer of polylactic acid/polycaprolactone. - View Dependent Claims (27)
-
-
28. An implantable stent prosthesis for delivering a biologically active material to a patient comprising:
-
(a) a stent body having a surface adapted for exposure to body tissue of the patient;
(b) a coating disposed over at least a portion of the surface of the stent body;
wherein the coating comprises;
(i) a biologically active material selected from the group consisting of anti-thrombogenic agents, anti-angiogenesis agents, anti-proliferative agents, growth factors, radiochemicals, and lovastatin; and
(ii) a mixture of a first polymer and a second polymer, wherein said first polymer releases the biologically active material at a first rate and said second polymer releases the biologically active material at a second rate, wherein said second rate is slower than said first rate.- View Dependent Claims (29, 30, 31)
-
-
32. A method of making an implantable stent prosthesis for delivering a biologically active material to a patient, wherein said method comprises:
-
(a) providing a stent body having a surface adapted for exposure to body tissue of the patient;
(b) applying a coating over at least a portion of said surface;
wherein said coating comprises;
(i) a biologically active material selected from the group consisting of anti-thrombogenic agents, anti-angiogenesis agents, anti-proliferative agents, growth factors, radiochemicals, and lovastatin; and
(ii) a mixture of a first polymer and a second polymer, wherein said first polymer releases said biologically active material at a first rate and said second polymer releases said biologically active material at a second rate, and wherein said second rate is slower than said first rate.- View Dependent Claims (33, 34)
-
Specification